Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Concomitant Administration of Multiple Doses of Cagrilintide With Semaglutide 2-4 mg for Weight Management
Q&A Session with Dr. Danielle Salha
Renowned for our full-service offering, we often get asked — how does Altasciences manage the development process for biologics and biosimilars so seamlessly from the require
Bioanalytical Methods for Vaccine Assessment
Altasciences performs robust, bioanalytical assessments according to GLP and GCP regulations for a wide range of vaccine types, including: adjuvanted recombinant proteins, virus-like particles, and nucleic acid- or vector-based vaccines.
We apply our extensive expertise in diverse and complex biological matrices by utilizing broad platform capabilities, for the development of optimal, phase-appropriate methods that meet your unique vaccine program needs, such as:
- Flow Cytometry
- ELISA
- Cell-Based Functional Assays
- Meso Scale Discovery
- Real-Time PCR (qPCR) & Digital Droplet PCR (ddPCR)
Contact our scientists today.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
You may also be interested in the following:
- Fact Sheet: First-in-Human (FIH) Trials
- Webpage: Preclinical Drug Development Solutions
- Fact Sheet: Comprehensive Research Support
Interview with the North American 3Rs of Animals in Research Collaborative
Dr. LaFollette from NA3RsC Talks Animal Welfare!
Altasciences’ important role in the drug development process comes with the significant responsibility of ensuring the welfare of our research animals, a responsibility that we take extremely seriously.
Altasciences is committed to doing everything possible to minimize the number of animals used and ensure that the animals used are treated with care, dignity, and the utmost respect.
Dr. Christina Cruzen, Attending Veterinarian and Chief Animal Welfare Officer, had the opportunity to interview Dr. Megan R. LaFollette, Program Manager at The North American 3Rs of Animals in Research Collaborative (NA3RsC), to discuss the importance of animal welfare, the 3Rs, how the role of animal research is changing, rat tickling as a refinement technique, and much more.
Contact Dr. Cruzen to further discuss all things animal welfare.
You may also be interested in the following:
- Video: Feel the Love ― Altasciences' Animal Welfare Program
- Webpage: Full-Time Equivalent (FTE) Capabilities
- Insert: Bioanalytical Services ― General Overview
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.
Accelerate your Biologic/Biosimilar Program with Altasciences Laboratory Sciences
Your biologic or biosimilar drug development program deserves the best chance of success. Altasciences has demonstrated expertise and decades of experience in the development of large molecules, from preclinical safety testing to clinical proof of concept, including robust bioanalytical support, project management, and medical writing.
We have a wide range of large molecule bioanalytical capabilities, using both ligand binding and mass spectrometry platforms :
- Method development
- GCP/GLP-compliant biosimilar assay development and validation
- Sample analysis for PK and immunogenicity/anti-drug antibody (ADA) testing
To know more, please consult:
Our Q&A Session with Dr. Danielle Salha, Senior Director, Immunology and Immunochemistry, Ligand Binding Assays
The Altascientist, a scientific journal with detailed discussion of our bioanalytical capabilities (LC-MS/MS and Ligand Binding)
Contact our experts today for a customized experience.
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept.
You may also be interested in the following:
Initiating Rodent Toxicology Studies in 4 to 6 Weeks
Altasciences can initiate rodent toxicology studies in 4 to 6 weeks. As soon as your contract is signed, our experienced team of toxicologists will work closely with you to develop and employ strategies to help move your molecule through the drug development process as quickly as possible, by proactively identifying potential challenges and planning accordingly.
Selecting the right CRO for your studies is critical to the success of your research.
Make the right choice, contact us today.
You may also be interested in the following:
- The Altascientist: Planning your Preclinical Assessment
- The Altascientist: Safety Pharmacology Studies ― a Review
- Insert: Bioanalysis of Small Molecules
- Video: Your Road to Proactive Drug Development with Altasciences
- Webpage: Tell Us Once™
Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.
Up Close and Personal with Dr. Gaetano Morelli, MD
Dedicated to Medical training
He is a member of the Collège des Médecins du Québec, a Fellow of the Royal College of Physicians of Canada, certified in Internal Medicine and
Prioritizing the Compassionate Care of Research Animals
The 3Rs of Animal Research
The 3Rs philosophy is the guiding principle for the Animal Welfare Program at Altasciences.
March 2021
In this issue
The latest complimentary webinars, industry podcasts and articles, bioanalytical assays, and more!
The Altascientist
Exploring microsampling applications, benefits, and considerations in preclinical, clinical, and bioanalytical research during early phase drug development. Includes two case studies!
Making Early Phase Drug Development More Efficient
Engaging with a single partner through the critical early stages can make all the difference.
Timely PK Analysis Supports Data-Driven Decisions
Exploring the benefits of including pharmacokinetic analysis between cohorts in first-in-human studies.
Industry News
Keep up to date on the latest news from and about Altasciences.
CONTINUE READING
- Webinars
View the latest on-demand webinars and catch up on some of our favorites, including a new presentation on navigating the abuse potential evaluation of CNS-active drugs for European and American submissions. - Podcasts
HListen to discussions about the principles of the 3Rs in preclinical studies, large molecule bioanalysis, Altasciences’ unique approach to scientific project management, and research support services. - Up Close and Personal with…
Meet Dr. Gaetano Morelli, Chief Medical Officer at Altasciences. - Blog
Learn more about protocol design concepts in Phase I ethnobridging clinical trials.
